youtube_live
Q3 2026 earnings • 8:00 AM tomorrow
See detailschevron_right
BNTX:NASDAQ
BioNTech SE - ADR
$87.53
arrow_downward
-0.73%(-0.64) 1D
$87.53
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:02 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$88.20
High
$88.74
Low
$87.20
Mkt. cap
21.99B
Avg. vol.
1.05M
Volume
709.98K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.49
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
Open
$88.20
High
$88.74
Low
$87.20
Mkt. cap
21.99B
Avg. vol.
1.05M
Volume
709.98K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.49
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
Investing.com
·
9 hours ago
BioNTech earnings up next: Can revenue rebound offset cancer setback?
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR
Analyst ratings
Based on 15 analysts giving stock ratings to BNTX in the past 3 months
Buy
Buy
11
Hold
4
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for BNTX in the last 3 months.
Highest
Current $87.53
$140.00 (+59.95%)
Average
$125.85 (+43.78%)
Lowest
$96.00 (+9.68%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Terence Flynn Morgan Stanley | Buy | Reiterated | $114.00 | +30.2% | 11/02/2026 |
Jessica Fye J.P. Morgan | Hold | Maintained | - | - | 10/27/2026 |
John Newman Canaccord Genuity | Buy | Maintained | $132.00 | +50.8% | 10/27/2026 |
David Dai UBS | Buy | Maintained | $135.00 | +54.2% | 10/26/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Maintained | $114.00 | +30.2% | 10/27/2026 |
Geoff Meacham Citi | Buy | Maintained | $125.00 | +42.8% | 10/27/2026 |
Asad Haider Goldman Sachs | Buy | Maintained | $127.00 | +45.1% | 10/13/2026 |
Cory Kasimov Evercore ISI | Buy | Maintained | $130.00 | +48.5% | 10/13/2026 |
Evan Seigerman BMO Capital | Hold | Maintained | $105.00 | +20% | 10/12/2026 |
John Eade Argus Research | Hold | Initiated | - | - | 10/07/2026 |
Harry Gillis Berenberg Bank | Buy | Maintained | $140.00 | +59.9% | 10/07/2026 |
Luisa Hector Berenberg Bank | Buy | Maintained | $140.00 | +59.9% | 10/07/2026 |
Jeffrey Walch Bernstein | Hold | Maintained | $96.00 | +9.7% | 09/25/2026 |
Mohit Bansal Wells Fargo | Buy | Maintained | $140.00 | +59.9% | 09/24/2026 |
Akash Tewari Jefferies | Buy | Maintained | $138.00 | +57.7% | 09/15/2026 |
Emmanuel Papadakis Deutsche Bank | Buy | Maintained | $140.00 | +59.9% | 08/26/2026 |
Unknown Analyst Wells Fargo | Buy | Maintained | $140.00 | +59.9% | 08/05/2026 |
Unknown Analyst Bernstein | Hold | Maintained | - | - | 06/01/2026 |
Unknown Analyst J.P. Morgan | Hold | Maintained | $100.00 | +14.2% | 05/20/2026 |
Yaron Werber TD Cowen | Hold | Maintained | $94.00 | +7.4% | 05/05/2026 |
Robert Burns H.C. Wainwright | Buy | Reiterated | $130.00 | +48.5% | 04/27/2026 |
Asthika Goonewardene Truist Financial | Buy | Maintained | $155.00 | +77.1% | 03/13/2026 |
William Maughan Clear Street | Buy | Reiterated | $167.00 | +90.8% | 03/11/2026 |
Daina Graybosch Leerink Partners | Hold | Downgraded | $113.00 | +29.1% | 02/02/2026 |
Next call in 10:57:22
Tomorrow, 8:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (EUR)
- GAAP EPS / Est. (EUR)
- / €0.76
Revenue / Est. (EUR)
- / 1.04B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in EUR | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.52B | 907.40M | 118.10M | 105.60M |
Cost of goods sold | 148.30M | 302.80M | 71.40M | 97.00M |
Cost of revenue | 148.30M | 302.80M | 71.40M | 97.00M |
Research and development expenses | 564.80M | 505.40M | 557.00M | 477.10M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 148.50M | 217.90M | 150.80M | 197.80M |
Operating expense | 1.40B | 907.20M | 727.70M | 860.40M |
Total operating expenses | 1.55B | 1.21B | 799.10M | 957.40M |
Operating income | -33.00M | -302.60M | -681.00M | -851.80M |
Other non operating income | 96.80M | -173.80M | 42.10M | 23.80M |
EBT including unusual items | 24.70M | -227.40M | -568.10M | -858.70M |
EBT excluding unusual items | 40.70M | -206.50M | -567.80M | -777.70M |
Income tax expense | 53.40M | 77.60M | -36.20M | -37.90M |
Effective tax rate | 216.19% | -34.12% | 6.37% | 4.41% |
Other operating expenses | 690.30M | 183.90M | 19.90M | 185.50M |
Net income | -28.70M | -305.00M | -531.90M | -820.80M |
Net profit margin | -1.89% | -33.61% | -450.38% | -777.27% |
Earnings per share | -0.12 | -0.33 | -1.95 | -2.22 |
Interest and investment income | - | 265.50M | 61.70M | 66.40M |
Interest expense | -2.60M | - | -4.00M | -3.50M |
Net interest expenses | -2.60M | 265.50M | 57.70M | 62.90M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 91.20M | -266.95M | -559.70M | -585.70M |
Gain or loss from assets sale | -1.30M | -800.00K | -100.00K | -900.00K |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events